Innovative approaches for cocaine pharmacotheraphy: the case of rimonabant.
- Conditions
- addiction, cocaine, relapse, dopamine, DA D2 receptor, rimonabant, dopamine, neuro-imaging, SPECT, fMRI
- Registration Number
- NL-OMON20293
- Lead Sponsor
- Prof. dr. Wim Van den Brinkdr. Jan Booijdr. Michelle Millerdrs. Cleo Crunelle
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1. Male, age 18-60 years
2. Current DSM-IV diagnosis of cocaine dependence, but recently detoxified and abstinent
Exclusion Criteria
1. Currently dependent on any substance other than cocaine or nicotine
2. History of depression that could be defined as even a single episode or recurrent episodes of depression, or depression necessitating hospitalization, or history of suicide attempt (see fotenote1)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the changes in DA D2 receptor availability in the striatum after 2 months of rimonabant treatment.<br>To assess whether rimonabant can decrease cocaine craving and/or impulsivity in human cocaine users.<br>To assess whether DA D2 receptor availability in the striatum can predict relapse to cocaine abuse in detoxified cocaine users.
- Secondary Outcome Measures
Name Time Method